Cargando…

Development and Characterization of a Preclinical Model of Breast Cancer Lung Micrometastatic to Macrometastatic Progression

Most cancer patients die with metastatic disease, thus, good models that recapitulate the natural process of metastasis including a dormancy period with micrometastatic cells would be beneficial in developing treatment strategies. Herein we report a model of natural metastasis that balances time to...

Descripción completa

Detalles Bibliográficos
Autores principales: Bailey-Downs, Lora C., Thorpe, Jessica E., Disch, Bryan C., Bastian, Anja, Hauser, Paul J., Farasyn, Taleah, Berry, William L., Hurst, Robert E., Ihnat, Michael A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4039511/
https://www.ncbi.nlm.nih.gov/pubmed/24878664
http://dx.doi.org/10.1371/journal.pone.0098624
_version_ 1782318500763664384
author Bailey-Downs, Lora C.
Thorpe, Jessica E.
Disch, Bryan C.
Bastian, Anja
Hauser, Paul J.
Farasyn, Taleah
Berry, William L.
Hurst, Robert E.
Ihnat, Michael A.
author_facet Bailey-Downs, Lora C.
Thorpe, Jessica E.
Disch, Bryan C.
Bastian, Anja
Hauser, Paul J.
Farasyn, Taleah
Berry, William L.
Hurst, Robert E.
Ihnat, Michael A.
author_sort Bailey-Downs, Lora C.
collection PubMed
description Most cancer patients die with metastatic disease, thus, good models that recapitulate the natural process of metastasis including a dormancy period with micrometastatic cells would be beneficial in developing treatment strategies. Herein we report a model of natural metastasis that balances time to complete experiments with a reasonable dormancy period, which can be used to better study metastatic progression. The basis for the model is a 4T1 triple negative syngeneic breast cancer model without resection of the primary tumor. A cell titration from 500 to 15,000 GFP tagged 4T1 cells implanted into fat pad number four of immune proficient eight week female BALB/cJ mice optimized speed of the model while possessing metastatic processes including dormancy and beginning of reactivation. The frequency of primary tumors was less than 50% in animals implanted with 500–1500 cells. Although implantation with over 10,000 cells resulted in 100% primary tumor development, the tumors and macrometastases formed were highly aggressive, lacked dormancy, and offered no opportunity for treatment. Implantation of 7,500 cells resulted in >90% tumor take by 10 days; in 30–60 micrometastases in the lung (with many animals also having 2–30 brain micrometastases) two weeks post-implantation, with the first small macrometastases present at five weeks; many animals displaying macrometastases at five weeks and animals becoming moribund by six weeks post-implantation. Using the optimum of 7,500 cells the efficacy of a chemotherapeutic agent for breast cancer, doxorubicin, given at its maximal tolerated dose (MTD; 1 mg/kg weekly) was tested for an effect on metastasis. Doxorubicin treatment significantly reduced primary tumor growth and lung micrometastases but the number of macrometastases at experiment end was not significantly affected. This model should prove useful for development of drugs to target metastasis and to study the biology of metastasis.
format Online
Article
Text
id pubmed-4039511
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-40395112014-06-02 Development and Characterization of a Preclinical Model of Breast Cancer Lung Micrometastatic to Macrometastatic Progression Bailey-Downs, Lora C. Thorpe, Jessica E. Disch, Bryan C. Bastian, Anja Hauser, Paul J. Farasyn, Taleah Berry, William L. Hurst, Robert E. Ihnat, Michael A. PLoS One Research Article Most cancer patients die with metastatic disease, thus, good models that recapitulate the natural process of metastasis including a dormancy period with micrometastatic cells would be beneficial in developing treatment strategies. Herein we report a model of natural metastasis that balances time to complete experiments with a reasonable dormancy period, which can be used to better study metastatic progression. The basis for the model is a 4T1 triple negative syngeneic breast cancer model without resection of the primary tumor. A cell titration from 500 to 15,000 GFP tagged 4T1 cells implanted into fat pad number four of immune proficient eight week female BALB/cJ mice optimized speed of the model while possessing metastatic processes including dormancy and beginning of reactivation. The frequency of primary tumors was less than 50% in animals implanted with 500–1500 cells. Although implantation with over 10,000 cells resulted in 100% primary tumor development, the tumors and macrometastases formed were highly aggressive, lacked dormancy, and offered no opportunity for treatment. Implantation of 7,500 cells resulted in >90% tumor take by 10 days; in 30–60 micrometastases in the lung (with many animals also having 2–30 brain micrometastases) two weeks post-implantation, with the first small macrometastases present at five weeks; many animals displaying macrometastases at five weeks and animals becoming moribund by six weeks post-implantation. Using the optimum of 7,500 cells the efficacy of a chemotherapeutic agent for breast cancer, doxorubicin, given at its maximal tolerated dose (MTD; 1 mg/kg weekly) was tested for an effect on metastasis. Doxorubicin treatment significantly reduced primary tumor growth and lung micrometastases but the number of macrometastases at experiment end was not significantly affected. This model should prove useful for development of drugs to target metastasis and to study the biology of metastasis. Public Library of Science 2014-05-30 /pmc/articles/PMC4039511/ /pubmed/24878664 http://dx.doi.org/10.1371/journal.pone.0098624 Text en © 2014 Bailey-Downs et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Bailey-Downs, Lora C.
Thorpe, Jessica E.
Disch, Bryan C.
Bastian, Anja
Hauser, Paul J.
Farasyn, Taleah
Berry, William L.
Hurst, Robert E.
Ihnat, Michael A.
Development and Characterization of a Preclinical Model of Breast Cancer Lung Micrometastatic to Macrometastatic Progression
title Development and Characterization of a Preclinical Model of Breast Cancer Lung Micrometastatic to Macrometastatic Progression
title_full Development and Characterization of a Preclinical Model of Breast Cancer Lung Micrometastatic to Macrometastatic Progression
title_fullStr Development and Characterization of a Preclinical Model of Breast Cancer Lung Micrometastatic to Macrometastatic Progression
title_full_unstemmed Development and Characterization of a Preclinical Model of Breast Cancer Lung Micrometastatic to Macrometastatic Progression
title_short Development and Characterization of a Preclinical Model of Breast Cancer Lung Micrometastatic to Macrometastatic Progression
title_sort development and characterization of a preclinical model of breast cancer lung micrometastatic to macrometastatic progression
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4039511/
https://www.ncbi.nlm.nih.gov/pubmed/24878664
http://dx.doi.org/10.1371/journal.pone.0098624
work_keys_str_mv AT baileydownslorac developmentandcharacterizationofapreclinicalmodelofbreastcancerlungmicrometastatictomacrometastaticprogression
AT thorpejessicae developmentandcharacterizationofapreclinicalmodelofbreastcancerlungmicrometastatictomacrometastaticprogression
AT dischbryanc developmentandcharacterizationofapreclinicalmodelofbreastcancerlungmicrometastatictomacrometastaticprogression
AT bastiananja developmentandcharacterizationofapreclinicalmodelofbreastcancerlungmicrometastatictomacrometastaticprogression
AT hauserpaulj developmentandcharacterizationofapreclinicalmodelofbreastcancerlungmicrometastatictomacrometastaticprogression
AT farasyntaleah developmentandcharacterizationofapreclinicalmodelofbreastcancerlungmicrometastatictomacrometastaticprogression
AT berrywilliaml developmentandcharacterizationofapreclinicalmodelofbreastcancerlungmicrometastatictomacrometastaticprogression
AT hurstroberte developmentandcharacterizationofapreclinicalmodelofbreastcancerlungmicrometastatictomacrometastaticprogression
AT ihnatmichaela developmentandcharacterizationofapreclinicalmodelofbreastcancerlungmicrometastatictomacrometastaticprogression